Recombinant CD274 (Durvalumab Biosimilar) antibody

Catalog No. ABIN7795090

This anti-CD274 (Durvalumab Biosimilar) antibody is a Humanized Monoclonal antibody detecting CD274 (Durvalumab Biosimilar) in FACS and in vivo. Suitable for Human.

Quick Overview for Recombinant CD274 (Durvalumab Biosimilar) antibody (ABIN7795090)

Target: CD274 (Durvalumab Biosimilar)

Antibody Type: Recombinant Antibody

Reactivity: Human

Host: Humanized

Clonality: Monoclonal

Conjugate: This CD274 (Durvalumab Biosimilar) antibody is un-conjugated

Application: Flow Cytometry (FACS), In vivo Studies (in vivo)

Grade: Research Grade

Product Details anti-CD274 (Durvalumab Biosimilar) Antibody

Expression System: Mammalian cells

Purpose: Durvalumab Biosimilar, PD-L1 Monoclonal Antibody

Characteristics: Durvalumab Biosimilar uses the same protein sequences as the therapeutic antibody durvalumab. PD-L1 and PD-L2 (B2-DC or CD273, programmed cell death ligand 2) are the two ligands for the receptor PD1 (CD279, programmed death 1). Durvalumab is a humanized monoclonal antibody directed against the human protein ligand PD-L1 (B7-H1 or CD274, programmed cell death ligand 1). Durvalumab completely blocks the binding of PDL1 to both PD-1 and CD80, with IC50s of 0.1 and 0.04 nM, respectively. Durvalumab is an anticancer antibody that works to promote the antitumor response mediated by immune cells. By blocking the action of PD-L1, durvalumab exerts its anticancer effects by increasing T-cell activation, enhancing detection and ablation of tumor cells. In in vitro assays, durvalumab inhibited the activity of PD-L1 in a concentration-dependent manner. In co-engrafted human tumor and immune cell xenograft mouse models, durvalumab was effective in decreasing tumor size. Durvalumab does not mediate antibody-dependent cell-mediated cytotoxicity (ADCC).

Purification: Protein A or G affinity column

Purity: >95 % by reducing SDS-PAGE

Endotoxin Level: < 1 EU per 1 mg of the protein by the LAL method

Immunogen: Human PD-L1

Application Details

Application Notes: Optimal working dilution should be determined by the investigator.

Restrictions: For Research Use only

Handling

Format: Liquid

Concentration: > 3 mg/mL

Storage: 4 °C,-20 °C

Storage Comment: Short time 2 to 8°C as supplied. Long time -20°C to -70°C as supplied.

Target Details for CD274 (Durvalumab Biosimilar)

Target: CD274 (Durvalumab Biosimilar)

Alternative Name: Durvalumab Biosimilar

Target Type: Biosimilar